Medication info

Linafty Duo Tablets 2.5/500 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Kooju Pharmaceutical Co., Ltd.
Appearance
Bright yellow, double-sided, convex oval film-coated tablet
Packaging
60 tablets/PTP [(10 tablets/PTP*6)]
Approval status
Expired

MFDS item code 201908690 · Approved 2019.12.30

This product's status changed to Expired on 2024.12.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this product should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This product is administered twice daily with meals. To reduce gastrointestinal adverse effects associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose of this product is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this product should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Inadequate glycemic control with combination therapy of insulin and metformin: The initial dose of this product should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this product is administered in combination with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see section 2, Precautions for Use in the Following Patients). No studies have evaluated the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this product. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this product, as the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, section 1, Do not administer to the following patients).

Ingredients

Manufacturer
Kooju Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used as an adjunct to diet and exercise to help control blood sugar in adults with type 2 diabetes. It is particularly administered in cases where blood sugar control is difficult with monotherapy in individuals who have not previously experienced diabetes medication treatment. Additionally, it is used to substitute for the combination therapy of linagliptin and metformin, and may be administered together with insulin when the efficacy of the combination of insulin and metformin is insufficient. If blood sugar control is difficult even with the maximum dosage of metformin combined with empagliflozin, this medication can be used alongside empagliflozin. Thus, it is a medication that helps improve blood sugar control in various therapeutic settings.

How to take

Adult dose

The dose of this product should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This product is administered twice daily with meals. To reduce gastrointestinal adverse effects associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose of this product is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this product should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Inadequate glycemic control with combination therapy of insulin and metformin: The initial dose of this product should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this product is administered in combination with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see section 2, Precautions for Use in the Following Patients). No studies have evaluated the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this product. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this product, as the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, section 1, Do not administer to the following patients).

Precautions

This medication can cause a rare serious side effect known as lactic acidosis, thus it should not be administered to patients with impaired liver or kidney function or those with certain heart conditions. Moreover, individuals allergic to any of the ingredients in this medication, patients with type 1 diabetes, pregnant or breastfeeding women, and those with acute infections or dehydration should not use it. Due to the risk of hypoglycemia, careful monitoring of blood sugar is necessary when taken with insulin or sulfonylureas, and adjustment of medication dosage should be performed as needed. Patients with reduced kidney function or the elderly should have regular kidney function tests performed, and if kidney function falls below a certain standard, this medication should not be taken. In the case of acute illness, surgery, or planned radiologic contrast examinations, this medication should be temporarily discontinued, and it may be resumed after kidney function has returned to normal. If symptoms such as sudden abdominal pain, muscle weakness, or difficulty breathing occur while taking this medication, medical consultation should be sought immediately, as these may indicate serious side effects like lactic acidosis or pancreatitis. Additionally, if skin blisters or rashes occur, one should immediately notify healthcare providers and discontinue the medication. As vitamin B12 levels may decrease, regular blood tests to check vitamin B12 status are advisable during long-term use. This medication may interact with several other medications, so it is essential to inform your doctor or pharmacist about any other medications you are taking, especially those that may affect kidney function. Women who are pregnant or planning to become pregnant are advised not to use this medication and should select other safe treatment methods for blood sugar control. Breastfeeding women should also avoid this medication, and it is not to be used in children under 10 years old. The elderly should initiate treatment with a lower dose due to the risk of reduced kidney function and require regular kidney function tests. In case of overdose, the risk of lactic acidosis increases greatly, so immediate medical treatment should be sought, and it may require blood dialysis. This medication should be stored out of reach of children, protected from moisture, and should not be transferred to another container.

Side effects

  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • lactic acidosis
  • vitamin B12 decrease and deficiency
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
Show 146 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe joint pain with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • diarrhea
  • hypoglycemia
  • stomatitis
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypertension
  • anxiety
  • insomnia
  • depression
  • bruising
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • insomnia
  • dizziness
  • drowsiness
  • pruritus
  • unstable angina
  • palpitations
  • dry eye
  • cataracts
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid goiter
  • confusion state
  • nocturia
  • dermatitis
  • hypertension
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • increased blood creatinine
  • facial edema
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • diabetic neuropathy
  • headache
  • subdural effusion
  • corneal abrasion
  • fall
  • ligament sprain
  • upper limb fracture
  • voice disorder
  • dyspnea
  • epistaxis
  • vocal cord polyp
  • dyslipidemia
  • hypercholesterolemia
  • myelodysplastic syndrome
  • papilloma
  • thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, therefore it should be stored in a sealed container. It is best stored at room temperature, between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Bright yellow, double-sided, convex oval film-coated tablet

Package unit

60 tablets/PTP [(10 tablets/PTP*6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.